Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
No abstract text is available yet for this article.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app